Optimization of cat-354, a therapeutic antibody directed against interleukin-13, using ribosome display

Methods in Molecular Biology

Volumn 805, Issue , 2012, Pages 393-401

  Thom, George ^a   Minter, Ralph ^a  

^a MEDIMMUNE   (United States)

Author keywords

Antibody; Interleukin 13; Protein evolution; Ribosome display; ScFv

Indexed keywords

INTERLEUKIN 13; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; ASTHMA; DIRECTED MOLECULAR EVOLUTION; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; RIBOSOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ASTHMA; DIRECTED MOLECULAR EVOLUTION; HUMANS; INTERLEUKIN-13; RIBOSOMES;

EID: 84555196323     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-379-0_22     Document Type: Article

References (16)

1. Reichert, J. M. Antibodies to watch in 2010, mAbs 2, 84-100.
2. Thompson, J., Pope, T., Tung, J. S., Chan, C., Hollis, G., Mark, G., and Johnson, K. S. (1996) Affi nity maturation of a high-affi nity human monoclonal antibody against the third hypervariable loop of human immunodefi ciency virus: use of phage display to improve affi nity and broaden strain reactivity, Journal of molecular biology 256, 77-88.
3. Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., Halpern, W. G., Lappin, P. B., Riccobene, T., Abramian, D., Sekut, L., Sturm, B., Poortman, C., Minter, R. R., Dobson, C. L., Williams, E., Carmen, S., Smith, R., Roschke, V., Hilbert, D. M., Vaughan, T. J., and Albert, V. R. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator, Arthritis and rheumatism 48, 3253-3265. (Pubitemid 37409340)
4. Thom, G., Cockroft, A. C., Buchanan, A. G., Candotti, C. J., Cohen, E. S., Lowne, D., Monk, P., Shorrock-Hart, C. P., Jermutus, L., and Minter, R. R. (2006) Probing a protein-protein interaction by in vitro evolution, Proceedings of the National Academy of Sciences of the United States of America 103, 7619-7624.
5. Hanes, J., and Pluckthun, A. (1997) In vitro selection and evolution of functional proteins by using ribosome display, Proceedings of the National Academy of Sciences of the United States of America 94, 4937-4942. (Pubitemid 27214714)
6. Caramori, G., Ito, K., and Adcock, I. M. (2004) Targeting Th2 cells in asthmatic airways, Current drug targets 3, 243-255. (Pubitemid 39213903)
7. Lewis, L., and Lloyd, C. (2010) Optimisation of antibody affi nity by ribosome display using sitedirected or error-prone mutagenesis, in Ribosome Display and Related Display Technologies: Methods and Protocols (Jackson, R. H., and Douthwaite, J., Eds.), Humana Press, New York.
8. Kabat, E. A. Sequences of proteins of immunological interest 5th ed, Bethesda, MD : U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1991. NIH publication ; no. 91-3242.
9. Hawkins, R. E., Russell, S. J., and Winter, G. (1992) Selection of phage antibodies by binding affi nity. Mimicking affi nity maturation, Journal of molecular biology 226, 889-896.
10. Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., and Johnson, K. S. (1996) Human antibodies with sub-nanomolar affi nities isolated from a large non-immunized phage display library, Nature biotechnology 14, 309-314.
11. Persic, L., Roberts, A., Wilton, J., Cattaneo, A., Bradbury, A., and Hoogenboom, H. R. (1997) An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene 187, 9-18. (Pubitemid 27110429)
12. Karlsson, R., Michaelsson, A., and Mattsson, L. (1991) Kinetic analysis of monoclonal antibodyantigen interactions with a new biosensor based analytical system, Journal of immunological methods 145, 229-240.
13. Miyazaki, K., and Arnold, F. H. (1999) Exploring nonnatural evolutionary pathways by saturation mutagenesis: rapid improvement of protein function, Journal of molecular evolution 49, 716-720. (Pubitemid 32250298)
14. Blanchard, C., Mishra, A., Saito-Akei, H., Monk, P., Anderson, I., and Rothenberg, M. E. (2005) Inhibition of human interleukin-13-induced respiratory and oesophageal infl ammation by anti-human-interleukin-13 antibody (CAT-354), Clin Exp Allergy 35, 1096-1103. (Pubitemid 41603145)
15. Oh, C. K., Faggioni, R., Jin, F., Roskos, L. K., Wang, B., Birrell, C., Wilson, R., and Molfi no, N. A. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males, British journal of clinical pharmacology 69, 645-655.
16. Singh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L., and Woodcock, A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma, BMC pulmonary medicine 10, 3.